Skip to main content
. 2022 Jul 29;7:45. doi: 10.1038/s41525-022-00316-x

Fig. 5. Magnitude of clinical utility of ACMG-based 4-Tier carrier screening.

Fig. 5

Frequency of at-risk couples and risk-reduction potential for NDDs according to a stepwise addition of the variant classification groups (1–14) are shown for nonconsanguineous and consanguineous couples for carrier screening for each of the 4-tiers recommended by the American College of Medical Genetics and Genomics (ACMG). In this carrier screening, Tier-1 includes screening of CFTR, SMN1 and medically and family-based risk genes, Tier-2 includes Tier-1 plus genes with carrier frequency ≥ 1/100, Tier-3 includes Tier-2 plus genes with carrier frequency ≥ 1/200 as well as X-linked conditions, and Tier-4 includes Tier-3 plus genes with carrier frequency < 1/200.